Technical Analysis for PTCT - PTC Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 25.32 | 2.55% | 0.63 |
Earnings due: Apr 25
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Bullish Engulfing | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Up 3% | about 8 hours ago |
| 60 Minute Opening Range Breakout | about 8 hours ago |
| Rose Above Previous Day's High | about 8 hours ago |
| Up 2% | about 8 hours ago |
| Up 1% | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 04/25/2024
PTC Therapeutics, Inc. Description
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Dystrophy Gene Expression Muscular Dystrophy Cystic Fibrosis Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 59.75 |
| 52 Week Low | 17.53 |
| Average Volume | 880,871 |
| 200-Day Moving Average | 29.06 |
| 50-Day Moving Average | 27.99 |
| 20-Day Moving Average | 27.33 |
| 10-Day Moving Average | 26.14 |
| Average True Range | 1.35 |
| RSI (14) | 38.27 |
| ADX | 24.24 |
| +DI | 9.60 |
| -DI | 24.11 |
| Chandelier Exit (Long, 3 ATRs) | 26.88 |
| Chandelier Exit (Short, 3 ATRs) | 28.07 |
| Upper Bollinger Bands | 30.27 |
| Lower Bollinger Band | 24.39 |
| Percent B (%b) | 0.16 |
| BandWidth | 21.49 |
| MACD Line | -0.98 |
| MACD Signal Line | -0.67 |
| MACD Histogram | -0.3118 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 27.63 | ||||
| Resistance 3 (R3) | 27.45 | 26.50 | 27.25 | ||
| Resistance 2 (R2) | 26.50 | 25.91 | 26.59 | 27.12 | |
| Resistance 1 (R1) | 25.91 | 25.55 | 26.21 | 26.09 | 26.99 |
| Pivot Point | 24.96 | 24.96 | 25.11 | 25.05 | 24.96 |
| Support 1 (S1) | 24.37 | 24.37 | 24.67 | 24.55 | 23.65 |
| Support 2 (S2) | 23.42 | 24.01 | 23.51 | 23.52 | |
| Support 3 (S3) | 22.83 | 23.42 | 23.40 | ||
| Support 4 (S4) | 23.01 |
